A Multicenter Randomized Phase II Study of Docetaxel/Carboplatin Versus Docetaxel/Pegylated Liposomal Doxorubicin as Second Line Treatment in Patients With Platinum Sensitive Disease.

Trial Profile

A Multicenter Randomized Phase II Study of Docetaxel/Carboplatin Versus Docetaxel/Pegylated Liposomal Doxorubicin as Second Line Treatment in Patients With Platinum Sensitive Disease.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 30 Sep 2015

At a glance

  • Drugs Docetaxel (Primary) ; Doxorubicin liposomal (Primary) ; Carboplatin
  • Indications Ovarian cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 30 Sep 2015 Status changed from withdrawn prior to enrolment to discontinued as reported by ClinicalTrials.gov.
    • 20 May 2011 Planned end date changed from 1 Feb 2011 to 1 Mar 2011 as reported by ClinicalTrials.gov.
    • 20 May 2011 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top